ASTRO 2023
Get the latest research and practical clinical applications from ASTRO 2023, including focused coverage on prostate, kidney, and penile cancer data.
18F-rhPSMA-7.3 PET may serve as a useful treatment planning tool for early biochemical recurrent prostate cancer.
Investigators used plasma samples from the ORIOLE study to conduct a blind validation study based on this new research.
According to new data, concerns surrounding the efficacy of 19-20 Gy single-dose HDR-BT as a monotherapy may be unfounded.
The previously reported nomogram demonstrated a prognostic utility for the prediction of OS.
While the low-dose arm required more salvage therapy, dose-escalated RT resulted in lower rates of DM.
New data compares renal function outcomes of SABR in patients with solitary versus bilateral kidneys.
Analysis of MIBC samples from the NRG/RTOG 0524 and 0712 studies has helped shed light on the tumor immune microenvironment.
The use of a SABR boost followed by chemoradiation to the pelvis was found to be well-tolerated in patients with MIBC.
Long-term DFS was noninferior in hypofractionated radiotherapy compared with conventional radiotherapy.
Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC.
Precision medicine navigators increase the likelihood that Black patients with prostate cancer will receive genomic testing.
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation.
Intermediate-risk PC can be treated as effectively with SBRT as with conventional radiation, according to 5-year results.
Advertisement
Advertisement
